Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Anti-CD20 monoclonal antibodies (mAbs) are classified into type I (rituximab-like) or type II (tositumomab-like) based on their ability to redistribute CD20 molecules in the plasma membrane and activate various effector functions. To compare type I and II mAbs directly in vivo and maximize Fc effector function, we selected and engineered mAbs with the same mouse IgG(2)a isotype and assessed their B-cell depleting activity in human CD20 transgenic mice. Despite being the same isotype, having similar affinity, opsonizing activity for phagocytosis, and in vivo half-life, the type II mAb tositumomab (B1) provided substantially longer depletion of B cells from the peripheral blood compared with the type I mAb rituximab (Rit m2a), and 1F5. This difference was also evident within the secondary lymphoid organs, in particular, the spleen. Failure to engage complement did not explain the efficacy of the type II reagents because type I mAbs mutated in the Fc domain (K322A) to prevent C1q binding still did not display equivalent efficacy. These results give support for the use of type II CD20 mAbs in human B-cell diseases.

Original publication

DOI

10.1182/blood-2008-04-149161

Type

Journal article

Journal

Blood

Publication Date

15/11/2008

Volume

112

Pages

4170 - 4177

Keywords

Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Murine-Derived, Antibody-Dependent Cell Cytotoxicity, Antigens, CD20, Antineoplastic Agents, Complement Activation, Complement C1q, Drug Evaluation, Preclinical, Humans, Immunoglobulin Constant Regions, Lymphocyte Depletion, Mutation, Missense, Protein Binding, Receptors, IgG, Rituximab